INVESTOR ALERT: Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. Announced by Glancy Binkow & Goldberg LLP

  INVESTOR ALERT: Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.
  Announced by Glancy Binkow & Goldberg LLP

Business Wire

LOS ANGELES -- February 27, 2014

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been
filed on behalf of all purchasers of the securities of Intercept
Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) between
January 9, 2014 and January 10, 2014, inclusive (the “Class Period”).

For more information, please contact us toll-free at 888-773-9224, or at
212-682-5340, or by email to shareholders@glancylaw.com to discuss this
matter.

Intercept is a development stage biopharmaceutical company, focused on the
development and commercialization of novel therapeutics to treat chronic liver
diseases utilizing Intercept’s proprietary bile acid chemistry. The Company’s
primary drug compound, obeticholic acid (“OCA”), is in various stages of
clinical development for the treatment of cirrhosis and other chronic liver
diseases. The complaint filed in the United States District Court for the
Southern District of New York alleges that the Company’s January 9, 2014, and
January 10, 2014, announcements concerning the Phase 2 clinical trial of OCA
for treatment of non-alcoholic steatohepatitis failed to disclose material
information.

On January 10, 2014, the National Institutes of Health’s National Institute of
Diabetes and Digestive Kidney Diseases issued a statement that although the
efficacy primary endpoint for OCA had already been met, study participants
suffered disproportionate levels of lipid abnormalities. Following this news,
Intercept stock dropped from its $445.83 per share closing price on January
10, 2014, to a closing price of $255.12 per share on January 14, 2014.

If you purchased Intercept securities during the Class Period, you have until
April 22, 2014, to move the Court to serve as lead plaintiff. If you wish to
learn more about this action, or have any questions concerning this
announcement or your rights or interests with respect to these matters, please
contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at
888-773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg
LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at
212-682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include your mailing
address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.